- Home
- STRM vs MTVA Comparison
STRM vs MTVA Comparison
Compare STRM & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRM
- MTVA
- Stock Information
- Founded
- STRM 1989
- MTVA 2014
- Country
- STRM United States
- MTVA United States
- Employees
- STRM N/A
- MTVA N/A
- Industry
- STRM EDP Services
- MTVA
- Sector
- STRM Technology
- MTVA
- Exchange
- STRM Nasdaq
- MTVA NYSE
- Market Cap
- STRM 15.4M
- MTVA 12.5M
- IPO Year
- STRM 1996
- MTVA N/A
- Fundamental
- Price
- STRM $3.14
- MTVA $1.51
- Analyst Decision
- STRM
- MTVA Strong Buy
- Analyst Count
- STRM 0
- MTVA 1
- Target Price
- STRM N/A
- MTVA $12.00
- AVG Volume (30 Days)
- STRM 11.7K
- MTVA 27.0K
- Earning Date
- STRM 04-28-2025
- MTVA 05-08-2025
- Dividend Yield
- STRM N/A
- MTVA N/A
- EPS Growth
- STRM N/A
- MTVA N/A
- EPS
- STRM N/A
- MTVA N/A
- Revenue
- STRM $18,587,000.00
- MTVA N/A
- Revenue This Year
- STRM N/A
- MTVA N/A
- Revenue Next Year
- STRM $4.04
- MTVA N/A
- P/E Ratio
- STRM N/A
- MTVA N/A
- Revenue Growth
- STRM N/A
- MTVA N/A
- 52 Week Low
- STRM $1.85
- MTVA $1.29
- 52 Week High
- STRM $9.75
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- STRM 37.14
- MTVA N/A
- Support Level
- STRM $3.05
- MTVA N/A
- Resistance Level
- STRM $3.27
- MTVA N/A
- Average True Range (ATR)
- STRM 0.18
- MTVA 0.00
- MACD
- STRM -0.03
- MTVA 0.00
- Stochastic Oscillator
- STRM 12.68
- MTVA 0.00
About STRM Streamline Health Solutions Inc.
Streamline Health Solutions Inc provides transformational data-driven solutions for healthcare organizations. It provides computer software-based solutions through its looking glass platform. Its solutions include coding and CDI, coding audit, and financial management solutions. It offers various services, such as custom integration services, training services, electronic image conversion and database monitoring services. It sells its solutions and services in North America to hospitals and health systems, including physician practices, through its direct sales force and its reseller partnerships.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.